News and Announcements
Altech Chemicals Receives Approval for its Meckering Kaolin Deposit
- Published March 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Altech Chemicals Limited (ASX:ATC) is pleased to advise that the Department of Mines and Petroleum (WA) has approved the mining proposal and the associated mine closure plan for its Meckering kaolin deposit. The mining approval marks an important stage in the development of the Company’s proposed Meckering kaolin mine, which will provide feedstock for Altech’s proposed Malaysian high purity alumina (HPA) plant.
KEY TAKEAWAYS:
- Mining proposal approved for Altech’s Meckering kaolin deposit.
- Important development milestone for supply of kaolin feedstock to Malaysian high purity alumina (HPA) plant.
- Approval allows mining to proceed when required.
- Stage 1 mining over a two-month campaign stockpiling 3 years’ of HPA plant feedstock.
The approved submission specifically allows for mining activities to commence within the Company’s 100%- owned Meckering mining lease M70/1334, which is located approximately 140km east of Perth.
At Meckering, Altech plans to mine approximately 140,000 tonnes of kaolin once every three years; mining will take place in short two-month mining campaigns. The resultant raw kaolin ore will be stockpiled on site, then containerised into standard shipping containers at the rate of approximately 40,000tpa and shipped to Johor, Malaysia via the port of Fremantle, Western Australia.
Altech managing director Mr Iggy Tan said, “The Company is delighted to have received mining approval for the Meckering kaolin deposit. Whilst the Company will not need to commence mining kaolin until 2018, the approval of the mine is an important developmental milestone that has now been ticked off.
“The next step is the works approval application for the proposed loading facility at Meckering, which is assessed by the Department of Environment Regulation”, Mr Tan concluded.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
